The investment is led by Norsk Innovasjonskapital III AS, a leading
Norwegian VC firm in syndication with existing APIM investors, Sarsia
Seed (Bergen, Norway), Birk Venture and Ro Invest (Oslo, Norway).
APIM Therapeutics was established in 2009 as a result of several years
of scientific work at Prof. M. Otterlei’s laboratory at the Norwegian
University of Science and Technology (NTNU). This research has
identified a novel therapeutic intervention point relevant for the
treatment of a large variety of cancer cells including, among others,
bladder cancer and multiple myeloma.